BIODLINK-B (01875) rose more than 9% in Hong Kong trading. At the time of writing, the stock was up 8.02% to HK$4.85, with a turnover of HK$19.89 million.

The movement follows an announcement on March 18 from WUXI XDC (02268) stating that it has successfully received valid acceptances for 60% of BIODLINK's shares, making the takeover offer officially effective.

According to WUXI XDC, the final deadline for accepting the offer is 4:00 PM on March 31, 2026. Shareholders of BIODLINK will have the remaining time to decide whether to accept the offer. The final result of the takeover bid will be announced by 7:00 PM on March 31, 2026.

The acquisition plan was initially disclosed in January of this year, when WuXi Biologics, WUXI XDC, and BIODLINK jointly announced that WUXI XDC intended to acquire all issued shares of BIODLINK through a cash offer. The total consideration is approximately HK$3.091 billion (about RMB 2.762 billion), marking the first major M&A deal in the CXO industry this year.